Blue Jet Healthcare Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

There's been a notable change in appetite for Blue Jet Healthcare Limited (NSE:BLUEJET) shares in the week since its second-quarter report, with the stock down 13% to ₹562. Blue Jet Healthcare reported a serious miss, with revenue of ₹1.7b falling a huge 39% short of analyst estimates. The bright side is that statutory earnings per share of ₹3.01 were in line with forecasts. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the consensus from Blue Jet Healthcare's eight analysts is for revenues of ₹11.4b in 2026, which would reflect a small 4.0% decline in revenue compared to the last year of performance. Statutory earnings per share are forecast to decline 14% to ₹17.38 in the same period. Before this earnings report, the analysts had been forecasting revenues of ₹13.3b and earnings per share (EPS) of ₹21.68 in 2026. It looks like sentiment has declined substantially in the aftermath of these results, with a substantial drop in revenue estimates and a substantial drop in earnings per share numbers as well.

Check out our latest analysis for Blue Jet Healthcare

The analysts made no major changes to their price target of ₹865, suggesting the downgrades are not expected to have a long-term impact on Blue Jet Healthcare's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Blue Jet Healthcare, with the most bullish analyst valuing it at ₹1,100 and the most bearish at ₹600 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that revenue is expected to reverse, with a forecast 7.9% annualised decline to the end of 2026. That is a notable change from historical growth of 65% over the last year. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 11% per year. It's pretty clear that Blue Jet Healthcare's revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Blue Jet Healthcare. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Blue Jet Healthcare going out to 2028, and you can see them free on our platform here..

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Blue Jet Healthcare , and understanding this should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.